<qa>  What is the randomized, single-blind, 3-period crossover study in healthyThis is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety including immunogenicity of a single 6mg subcutaneous injection of CHS-1701 Coherus pegfligrastim or 6mg SC dose of Neulasta pegfilgrastim given during each period. 